Teva Can't Escape Insurers' Copaxone Generic Delay Case
A Vermont federal court has refused to toss a proposed class action from insurers accusing Teva Pharmaceuticals of delaying generic versions of multiple sclerosis treatment Copaxone but trimmed several claims under...To view the full article, register now.
Already a subscriber? Click here to view full article